Prof. Yaniv Erlich is the CEO of Eleven Tx. Since 2017, he was the Chief Science Officer of MyHeritage.com. Prior to this position, he was an Associate Professor of Computer Science and Computational Biology at Columbia University and a Fellow at the Whitehead Institute, MIT. Dr. Erlich is a TEDMED speaker (2018), the recipient of DARPA’s Young Faculty Award (2017), the Burroughs Wellcome Career Award (2013), Harold M. Weintraub award (2010), and the IEEE/ACM-CS HPC award (2008).

During his career, Shaul was the co-founder and the CEO of Ilan Bio, COO and VP BD of Forrest Innovations, and the COO at Tropic Biosciences. These companies focus on developing new technologies for breeding and propagating new species for agritech and biotech applications based on RNAi and CRISPR technologies. In addition, Shaul gained operational and leadership skills from his service as a Major in the Israeli Air Force. He holds academic degrees in Business and Political Science from the Inter-Disciplinary Center (IDC) Herzelia.

Prof. Hannon is a co-founder of Eleven Tx, bringing a long history in studies of RNA biology. He is the Royal Society Wolfson Research Professor of Cancer Molecular Biology and the Director of the Cancer Research UK Cambridge Institute at University of Cambridge. The Institute he oversees is one of the premier cancer research institutes in Europe with more than 450 investigators. He brings to Eleven more than 30 years of experience in molecular biology, disease biology, and technology development, with over 300 peer-reviewed publications that have been cited more than 150,000 times. Prof. Hannon is a Member of the U.S. National Academy of Sciences, a Member of the Academy of Medical Sciences, a Fellow of the Royal Society of London, and a Member of the European Molecular Biology Organization (EMBO). He has won a number of internationally recognized awards for his work and has trained numerous students and postdocs who populate elite universities and positions of influence in industry. .

Dr. Weissbrod is a machine learning and statistical genetics expert that led numerous projects in some of the world's top biomedical research groups in academy and industry, including Harvard University, Weizmann Institute, and IBM Research. He brings deep experience in team-leading, software development, and scientific research, spanning multiple open-source software packages and over 30 papers published in the world's top scientific journals.

Dr. Grossman brings deep knowledge of the pharma industry, with 15 years of experience focused on early stages, regulatory requirements, and the science-business interface. She was VP and Head of Early Stage Clinical Development of Teva Pharmaceuticals and received multiple awards, including Israel's 40 under 40 by the "The Marker" Magazine. She was also selected to be a fellow of the first cohort of 8400, the Israel leadership in health program.

Dr. Douek is the Chief of the Human Immunology Section at the Vaccine Research Institute of National Institute of Allergies and Infectious Diseases at the NIH. Dr. Douek’s role on the SAB is part of his official activities for the National Institutes of Health. He has 30 years of experience in immunology research with nearly 300 peer-reviewed publications. Dr. Douek is the recipient of the World AIDS Day Award, NIH’s Director Award, World’s top 50 scientists by Scientific American, and top 1% most cited scientists by the Web of Science and Thomson Reuters report “The World’s Most Influential Scientific Minds.”